影像学体成分异常与肝硬化患者长期死亡率之间的关系
这项回顾性分析纳入2018年1月至2023年8月诊断的158例肝硬化患者,采用第三腰椎水平CT评估骨骼肌质量、肌肉质量及内脏与皮下脂肪,并用竞争风险模型分析四种体成分状态与肝相关死亡的关系。结果显示仅肌少症患者死亡率高于体成分正常者,VSR、肌少症和肌脂肪变性为独立预测因子,随访期间体成分恶化与更高死亡风险相关。
要点
- 第三腰椎水平CT可评估骨骼肌质量、肌肉质量及内脏与皮下脂肪,用于肝硬化体成分分型。
- 仅肌少症患者肝相关死亡风险高于体成分正常者(Gray检验 P=0.006)。
- VSR(HR=1.10)、肌少症(HR=2.73)、肌脂肪变性(HR=2.39)为肝相关死亡的独立预测因子。
核心结论
- 体成分状态的进行性改变似乎与肝硬化患者肝相关死亡相关,关注骨骼肌及内脏与皮下脂肪的管理可能有助于改善肝硬化患者预后。
研究设计与样本
- 回顾性分析纳入158例肝硬化患者(平均[SD]年龄57.1[12.6]岁),诊断时间为2018年1月至2023年8月,采用第三腰椎水平CT评估体成分,以竞争风险模型分析四种体成分状态与肝相关死亡的关系,并应用Gray检验分析体成分动态变化与长期预后的关系。
关键影像表现/征象
- CT于第三腰椎水平评估骨骼肌质量、肌肉质量、内脏脂肪与皮下脂肪,据此分为正常、仅肌少症、仅肌脂肪变性及合并状态四种体成分状态。
- 158例中肌少症85例(60.1%),肌少症性肥胖22例(13.9%),肌脂肪变性68例(43.0%)。
诊断标准与关键数值
- 仅肌少症患者死亡率高于体成分正常者(Gray检验 P=0.006)。
- 仅肌脂肪变性(Gray检验 P=0.076)及肌少症合并肌脂肪变性(Gray检验 P=0.140)与体成分正常者比较未达统计学显著。
- 多变量分析显示VSR(HR=1.10 [1.01∼1.20],P=0.028)、肌少症(HR=2.73 [1.20∼6.22],P=0.017)和肌脂肪变性(HR=2.39 [1.10∼5.18],P=0.028)为肝相关死亡的显著独立预测因子。
- 随访期间体成分恶化者死亡风险显著高于体成分正常或缓解者(HR=7.63 [1.12∼51.14],P=0.036)。
临床应用与阅片要点
- 作者认为,关注骨骼肌以及内脏和皮下脂肪的管理可能有助于改善肝硬化患者的预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Emerging evidence on cirrhosis suggests a close correlation between abnormality in body composition characteristics and poor prognosis. This study aimed to evaluate the impact of dynamic changes in body composition on the prognostic outcomes in patients with cirrhosis.
METHODS: This retrospective analysis included 158 patients diagnosed as cirrhosis from January 2018 to August 2023. Skeletal muscle mass, muscle quality, visceral and subcutaneous adiposity were evaluated using computed tomography (CT) imaging at the third lumbar vertebra level. Competing risk model was performed four different body composition status (i.e., normal, only sarcopenia, only myosteatosis, and combined status) for liver-related mortality. We also explored the relationship between the dynamic change in body composition and long-term prognosis by applying Gray's test.
RESULTS: Of the 158 cirrhotic patients (mean [SD] age, 57.1 [12.6] years), sarcopenia was present in 85 (60.1 %) patients, while 22 (13.9 %) patients had sarcopenic obesity and 68 (43.0 %) had myosteatosis. Patients solely diagnosed with sarcopenia exhibited a higher mortality rate compared to those with normal body composition (Gray's test, P=0.006), while patients solely diagnosed with myosteatosis or with a combination of sarcopenia and myosteatosis did not reach statistical significance (Gray's test, P=0.076; P=0.140). Multivariable analysis also revealed that VSR (HR=1.10 [1.01∼1.20]; P=0.028), sarcopenia (HR=2.73 [1.20∼6.22], P=0.017) and myosteatosis (HR=2.39 [1.10∼5.18], P=0.028) were significant independent predictors of liver-related deaths. Otherwise, patients exhibiting aggravating body composition during follow-up period were associated with a significantly higher mortality risk compared to those with normal or remission body composition status (HR=7.63 [1.12∼51.14]; P=0.036).
CONCLUSION: Progressive alterations in body composition status appears to be associated with liver-related mortality in individuals with liver cirrhosis. Focusing on the management of skeletal muscle, along with visceral and subcutaneous adiposity, may contribute to improving the prognosis of cirrhotic patients.
引用
- Ren W, Zheng J, Yang S, et al. The relationship between imaging-based body composition abnormalities and long-term mortality in patients with liver cirrhosis. Eur J Radiol. 2024. PMID: 39197272. doi:10.1016/j.ejrad.2024.111707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。